Stryker Corporation is facing a significant drop in its stock price as allegations emerge that the company concealed its reliance on elective procedures, which account for 50% of its sales and were adversely affected by the COVID-19 pandemic. A report by Spruce Point Capital has raised serious questions about the company's financial transparency, prompting an investigation by Johnson Fistel, LLP, into potential violations of federal securities laws. Despite a strong market capitalization of $100.14 billion and anticipated growth in its MedSurg segment, concerns over its $16.4 billion debt and the bearish market sentiment surrounding these allegations pose risks for investors.
“Stryker · is · covering multiple areas including oral hygiene · true”
“Stryker · posted sales of · $14.4 billion in 2020 · true”
“Ben Axler · discusses · medical equipment maker Stryker · why the stock is risky”
“Johnson Fistel, LLP · is investigating · potential violations of the federal securities laws · Stryker Corporation”
“Spruce Point Capital Management, LLC · published · a short-seller report · Stryker”
“Stryker Corporation · is · a medical technology company”
“Stryker Corporation · operates through · two segments · MedSurg and Neurotechnology and Orthopedics and Spine”
“Spruce Point Capital Management · published · a report · alleging that Stryker has failed to disclose certain material facts”
“Spruce Point · stated that Stryker · failed to disclose inventory accounting challenges”
“Stryker · concealed from investors · its true exposure to elective procedures adversely impacted by the COVID-19 pandemic · 50% of sales”
“the price of Stryker shares · were down · over 4% in early morning trading · April 6, 2022”
“Stryker Corporation · has violated · federal securities laws”
